|
|
|
|
Biotech investment remains strong, especially in cell and gene therapies. Learn five key factors that help companies decide between in-house and outsourced process development to improve speed, scalability, and strategic alignment.
|
|
|
|
|
Effective bioprocess tech transfer ensures consistent performance and minimizes risk across sites. Discover how strategic planning and knowledge sharing can safeguard reproducibility and product quality during scale-up or site transitions.
|
|
|
|
|
Balancing analytical depth with clinical speed is critical for early-phase pDNA and mRNA therapies. Find out how teams can navigate structural complexity and regulatory demands without compromising development timelines or therapeutic integrity.
|
|
|
|
|
Plasmid DNA production in E. coli is a cornerstone of gene therapy and vaccine development. Explore how media selection and scale-up strategy influence plasmid DNA yield in E. coli, as well as which conditions support high-yield production and how to apply them to your upstream process for better consistency.
|
|
|
|
|
Examine how DOE-driven optimization with E. coli OneShot Top10 enables scalable, high-yield plasmid DNA production, as well as gain practical insights into upstream process design for improved efficiency, consistency, and biomanufacturing success.
|
|
|
|
|
|
|
